The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children

Rahman, Syed I.; Siegfried, Elaine C.; Flanagan, Katherine H.; Armbrecht, Eric S.

doi:10.1016/j.jaad.2013.10.001

Cited by 20 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, both ciclosporin and MTX were used at low doses, and there was a general lack of detail in the paper about how results were analysed. There have been three retrospective cohort studies with a total of 86 children treated with MTX for eczema, although one study included a further 16 children with psoriasis or nonspecified inflammatory skin disease . The children were aged between 2 and 18 years and were treated with MTX doses of up to 15 mg weekly, with the greatest effect noted within the first 12 weeks.…”

Section: Indicationsmentioning

confidence: 99%

British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016

Weatherhead²,

et al. 2016

View full text Add to dashboard Cite

Section: Indicationsmentioning

confidence: 99%

British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016

Weatherhead²,

et al. 2016

View full text Add to dashboard Cite

“…In keeping with our clinical experience, methotrexate had a longer onset of action than cyclosporine but a more durable relapse‐free period after discontinuation of the drug. The remaining evidence for the use of methotrexate in severe childhood AD comes from retrospective case series . The use of methotrexate in children for neoplastic and inflammatory disease, including linear morphea, psoriasis, inflammatory bowel disease, and juvenile idiopathic arthritis, has become more widespread and has a reasonable safety profile with well‐known, predictable adverse effects.…”

Section: Discussionmentioning

confidence: 99%

Methotrexate for Severe Childhood Atopic Dermatitis: Clinical Experience in a Tertiary Center

Dvořáková

O’Regan

Irvine

2017

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…4 In our search nine 31,33,[54][55][56][57][58][59][60] new publications were found. All studies were excluded; because of an unclear treatment regimen (n = 1), 54 a combination of an unclear treatment regimen and an unclear outcome measure (n = 1), 55 no separate data available on paediatric psoriasis (n = 1), 57 and systemic combination therapy (n = 6). 31,33,56,[58][59][60]…”

Section: Methotrexatementioning

confidence: 99%

Systemic treatments in paediatric psoriasis: a systematic evidence‐based update

Geel

Mul

Jager

et al. 2014

Acad Dermatol Venereol

View full text Add to dashboard Cite

In 2008, a systematic review revealed that evidence-based data on efficacy and safety of treatments in paediatric psoriasis are scarce and with low level of evidence. In recent years, publications on this topic have increased exponentially. To present a systematic, evidence-based update on the efficacy and safety of systemic treatments in paediatric psoriasis and to provide treatment recommendations, an update of the previous review was performed. PubMed, EMBASE and the Cochrane Controlled Clinical Trial Register were searched between January 2007 and March 2014 for all available literature on efficacy and safety of all systemic treatments in paediatric psoriasis. The levels of evidence were determined on the Oxford Centre for Evidence-based Medicine Levels of Evidence. The newly retrieved evidence was combined with the evidence available in the former review. Fifty-two studies were included: 36 from the former review, plus 16 new articles. New evidence on induction therapy was mainly available on fumaric acid esters (FAEs), which are shown to be effective in a subgroup of patients. Long-term (96 weeks) safety and efficacy data on etanercept were found. Prospective studies are scarce. Most conclusions are formulated on studies with low level of evidence. Of the conventional systemic treatments, methotrexate still has the most evidence albeit in a low number of patients and with a low level of evidence. FAEs seem to be effective in a subgroup of patients, with gastro-intestinal complaints, flushes and temporary shifts in leucocyte counts and liver enzymes being the main side-effects. Etanercept has still accumulated most evidence of the available systematic treatments, with a large efficacy and reassuring safety profile in a 96-week follow-up.

show abstract

The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children

Cited by 20 publications

References 9 publications

British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016

British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016

Methotrexate for Severe Childhood Atopic Dermatitis: Clinical Experience in a Tertiary Center

Systemic treatments in paediatric psoriasis: a systematic evidence‐based update

Contact Info

Product

Resources

About